Therapeutic effect of treatments on ejection retention fraction type heart failure

Heart failure (HF) is a chronic disease, accompanied with a heavy burden of manifestations of cardiac weakness, limitations of normal exercise and low quality of lives, which is prevalent in the citizens. Heart failure with persevered ejection fraction (HFpEF) patients manifests marked impairments in capacity of exercise, which impacts and lowers patients’ quality of daily lives. Currently, existent pharmacologic treatments are neutral and there are no proper therapies for HFpEF. In this case, ample scientists laid emphasis on the effect of diverse drugs on the treatment of HFpEF. The purpose of this paper is to summarize treatments that have potential clinical application and have been studied repeatedly by researchers. For those drugs that are used in a limited range in clinical practice, this paper can help medical workers to use them correctly and predict the effect, so as to expand the scope of application. For those treatments that have not yet been used in clinical practice, this paper may help medical workers and pharmaceutical companies to find new drugs that can be used in human body to improve the treatment effect and patient prognosis.